Lupoid cutaneous leishmaniasis: a case report by Aida Khaled et al.
Dermatol Ther (2011)  1(2):36-41.
DOI 10.1007/s13555-011-0008-9
CASE REPORT
To view enhanced content go to www.dermtherapy-open.com
Received: October 1, 2011 / Published online: 18 November, 2011
© The Author(s) 2011. This article is published with open access at Springerlink.com
Enhanced content for this article is 
available on the journal web site: 
www.dermtherapy-open.com
Lupoid Cutaneous Leishmaniasis: a Case Report
Aida Khaled · Samia Goucha · Sonia Trabelsi · Rachida Zermani · Bécima Fazaa
ABSTRACT
Background: Lupoid cutaneous leishmaniasis 
(CL) is a rare form of CL having a striking 
resemblance to other granulomatous cutaneous 
conditions of infectious or inflammatory 
origin. The authors present a patient with a 
facial lupoid CL and discuss the diagnostic 
tools of this parasitological infection, the 
main differential diagnosis, and treatment. 
Case report: A 54-year-old Tunisian woman, with 
no past medical history of lupus erythematosus 
or infectious disease, presented with a 3-month 
history of a slowly enlarging erythematous and 
infiltrated plaque, extending over the nose, 
the right cheek, and the internal aspect of the 
right lower eyelid. Microscopic examination 
of a parasitological smear showed numerous 
leishmania in their amastigote form, inside 
monocytes, confirming the diagnosis of CL. 
Clinical aspect was in favor of lupoid CL. The 
patient was cured by fluconazole 200 mg/day
for 6 weeks after pancreatic intolerance 
with intramuscular meglumine antimoniate 
(60 mg/kg/day for 7 days), and no response to 
doxycycline (200 mg/day for 6 weeks). Discussion: 
Lupoid CL is easily suspected in countries in 
which there is an endemic of leishmaniasis. In 
countries where there isn’t an endemic, although 
rarely observed, this diagnosis should also be kept 
in mind in front of an infiltrated facial lesion of a 
tuberculoid aspect on histology, especially when 
there is a positive travel history to an area in 
which there is an endemic.
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BACKGROUND
Cutaneous leishmaniasis (CL) is a widespread 
parasitic disease in Tunisia with numerous 
clinical presentations. The authors report a 
case of facial lupoid CL in a Tunisian patient. 
Lupoid leishmaniasis is the most common CL 
among patients with unusual presentations.1 
The authors present its clinical feature, the 
diagnostic tools, differential diagnosis, course, 
and treatment of this uncommon long-lasting 
form of CL.
CASE REPORT
A 54-year-old Tunisian woman, with no past 
medical history, presented with a 3-month 
history of a slowly enlarging erythematous 
plaque of the central face. The patient had no 
other complaint. She was born and lived in a 
North-West city of Tunisia. The lesion started as a 
small, asymptomatic papule that slowly increased 
in size. Cutaneous examination showed a large 
solitary erythematous and infiltrated plaque, 
extending over the nose, a large part of the 
right cheek, and reaching the internal aspect of 
the right lower eyelid. Over the nose, the lesion 
appeared slightly squamous (Figure 1). Physical 
examination was otherwise normal; there was 
no fever or palpable lymph nodes. The patient 
did not respond to oral amoxicillin (4 g/day) 
for 10 days, prescribed by another physician 
before she was referred to our department. 
A parasitological smear after a skin scraping was 
performed. The resulting tissue was smeared on 
a slide and stained with May Grünwald Giemsa 
(Merck K GaA, 64271, Darmstadt, Germany). 
Microscopic examination showed numerous 
leishmania appearing in their amastigote form, 
outside monocytes (Figure 2), confirming the 
clinical suspicion of CL. Clinical aspect evoked 
the lupoid form of CL. The patient was treated 
with intramuscular injections of meglumine 
antimoniate (MA), 60 mg/kg/day. On the 7th 
day of treatment, she had elevated levels of serum 
amylase (two times the normal level) with high 
urine amylases. MA was stopped and replaced by 
doxycycline 200 mg/day for 6 weeks. The latter 
therapy was inefficient with extension of the 
plaque over the left cheek. She then underwent 
fluconazole 200 mg/day for 6 weeks, with a 
significant improvement of the lesion. 
DISCUSSION
CL is an infection caused by various species of 
leishmania protozoa. The parasite is inoculated 
Figure 1. Large erythematous and infiltrated plaque, 
extending over the nose, the right cheek and reaching the 
internal aspect of the right lower eyelid.
Figure 2. Extracellular amastigote form with the nucleus 
(a) and the kinetoplast (b).
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and transmitted by the bite of phlebotomine 
sandflies. Tunisia is a country where CL is 
frequent and there have been incidences in 
which there has been an endemic and an 
epidemic of Old World leishmaniasis.2 Thus, 
the diagnosis of CL was easily suspected in 
our patient, when presented with such a facial 
lesion having a chronic course with no signs of 
inflammation, pain, or pruritus. In Tunisia, there 
are three main epidemiological and clinical 
forms, depending on geographic origin and 
each due to a different species of leishmania: the 
sporadic CL, which is predominant in the North 
of Tunisia and caused by Leishmania infantum 
MON-24, the zoonotic form (Centre and South-
West of Tunisia) caused by Leishmania major 
MON-25, and the chronic CL occurring in 
the Southern-East of Tunisia and caused by 
Leishmania killicki.3 The most frequent form 
is the zoonotic form, which is epidemic with 
a seasonal outbreak especially in autumn and 
summer (mean of 3000-5000 cases per year).3 
In zoonotic CL, lesions have a rapid self-limiting 
evolution and in the absence of treatment, 
lesions heal in 6-8 months. In contrast, the 
chronic form is a long-lasting infection with a 
2-6 year duration having an endemic pattern 
along the year (50-100 cases per year).3,4
Since the patient originates from and lives 
in the North of Tunisia, our patient probably 
had the sporadic form of CL (L. infantum). The 
sporadic form is also a relatively long-lasting 
infection with a 1-2 year duration. It occurs at 
an incidence of 30 cases per year.3
The typical clinical presentation is an 
erythematous infiltrated, ulcerated, and crusted 
papule or nodule (classical oriental sore) of any 
region of the body, with a frequent involvement 
of exposed areas, especially the face and limbs. 
This typical lesion heals slowly over a period of 
3-12 months and constitutes the most frequent 
one.5 There are many other clinical forms of 
CL, among them the lupoid CL, observed in 
the present patient, which is a particularly 
uncommon form with characteristic spreading 
of the initial lesion leading to a solitary 
erythematous; infiltrated plaque with unlimited 
borders progressively confounding with 
adjacent normal skin. Sometimes, brown-red or 
brown-yellow papules appear and progressively 
coalesce and even lead to the formation of 
apple-jelly nodules, characteristic of the lupoid 
aspect of this form.6,7 The lesion may even be 
squamous with a psoriasiform aspect or produce 
crusts, and may closely resemble lupus vulgaris 
(LV). Although not as destructive as LV, lupoid 
CL may persist and spread for many years and 
aggravate gradually.7,8
Lupoid CL is most prevalent in the endemic 
areas of leishmaniasis, particularly in the Middle 
East and Afghanistan with a reported incidence 
of 0.5%-6.2% of all CL cases.9 In Tunisia, in a 
recent study including sporadic CL cases, lupoid 
CL represented 8.9% of cases in adults.10
It seems that in lupoid CL, the parasite is not 
killed, but it replicates inside the macrophage. 
These findings suggest that certain leishmanial 
strains, which induce chronic disease, may have 
the capacity to evade intracellular destruction by 
activated macrophages, or that there is a defect 
in the T-cell activation process.7,11
In lupoid CL, the amastigote forms are 
rare or absent on a parasitological smear.7,8
In this patient, there was fortunately a positive 
parasitological smear. This can be explained by 
the short course of the lesion (only 3 months) at 
the moment of diagnosis. 
Histologically, the aspect is that of a 
tuberculoid granuloma with giant multinucleated 
cells but without classification. Intra-macrophagic 
amastigotes are also rare or usually absent.7,8
In this form of CL, promastigotes are also 
difficult to maintain on Novy-MacNeal-Nicolle 
(NNN) medium, especially in sporadic CL due to 
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L. infantum. Although species-specific polymerase 
chain reaction (PCR) analysis is sensitive in 
cases of acute cutaneous leishmaniasis, Momeni 
et al. found lesser sensitivity of PCR in lupoid 
leishmaniasis (only 47%).6
In the literature, leishmania tropica is 
thought to be the most frequent causative agent 
of lupoid CL.7 In Tunisia, this form seems to be 
less rare with L. infantum and L. killicki.
In case of negative parasitological 
examination and in the absence of intra-
amastigotes on histology, diagnosis is made 
based on suggestive clinical aspect, facial 
localization, chronic evolution, and sometimes 
patients may recall the initial sandfly bite. 
All these criteria in a region where there is an 
endemic or epidemic of leishmaniasis, like 
Tunisia, or even in case of positive travel history 
to an endemic area, can aid in correct diagnosis. 
Despite all the above-mentioned arguments 
for the diagnosis of CL, when presented with 
such a facial lesion, the authors can evoke other 
diagnoses such as LV (cutaneous tuberculosis),12 
lupus erythematosus (LE), or lupus pernio, 
which is a form of cutaneous sarcoidosis and 
facial erysipelas.12,13
In the absence of randomized controlled 
trials, there is not enough data about the 
correct and selective therapeutic protocol 
for the treatment of lupoid CL. Pentavalent 
antimony compounds are, at present, the 
first choice of treatment. This is also the case 
in Tunisia, where most clinicians use either 
intralesional MA or intramuscular injection 
of MA 60 mg/kg/day for 15-20 days in cases 
of resistance to local injections, multiple 
lesions (>5), proximity to the cartilage, 
joint, and periorificial lesions.10 This dose is 
considered as the standard dose of systemic 
MA in the treatment of CL.14 Oral fluconazole 
has been shown to be safe and effective for 
CL with advantages particularly important 
in pediatrics;15,16 for some authors it may 
be a second line treatment.17 The patient 
responded adequately to fluconazole after 
MA intolerance. Many other treatments have 
been reported to be used as monotherapy 
in t reat ing CL such as  cryotherapy, 
paramomycin  o intment ,  int radermal 
injections of sodium stibogluconate, oral 
itraconazole, pentamidine, and miltefosine 
for the last few years. Lupoid CL is usually 
resistant to conventional therapies for CL 
and it may persist and spread slowly for many 
years.18,19 Due to possible resistance of lupoid 
CL to the previous modalities, combined 
therapies were tried. Momeni et al. reported 
a successful result with a combination of 
MA and allopurinol.20 Nilfrousihzadeh also 
showed that 17%, 57%, and 65% of complete 
cure of the lesions at the end of the 4th, 8th, 
and 10th week, respectively, were observed 
with combined cryotherapy, paramomycin, 
and intralesional MA in treating lupoid and 
chronic leishmaniasis,21 however, another 
study showed that carbon dioxide laser 
seems to be highly effective since it led to 
90% efficacy in treating 24 patients with 
lupoid CL,18 and another study reported 
16 cases who responded very well to MA 
without chronic infection or relapse, which 
suggests that lupoid CL should be revisited 
and redefined.7
CONCLUSION
In conclusion, while lupoid CL is an easily-
suspected diagnosis in endemic countries for 
leishmaniasis, outside endemic areas it can be 
mistaken for other disorders due to a clinical 
similarity. Thus, this diagnosis should be 
considered in patients who present an infiltrated 
facial plaque with a tuberculoid granuloma on 
histology.
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